Merck KGaA (MRK) News Today €138.10 -1.60 (-1.15%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Merck raises quarterly dividend to 81c from 77c per shareNovember 20 at 8:14 AM | markets.businessinsider.comMerck announces ‘positive’ results from Phase 3 MK-3475A-D77 trialNovember 19 at 10:04 PM | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on Merck KGaA (0O14)November 18 at 5:22 PM | markets.businessinsider.comIs Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now?November 18 at 5:22 PM | msn.comMerck receives CHMP opinion recommending approval of KeytrudaNovember 15, 2024 | markets.businessinsider.comMerck KGaA Q3 earnings rise faster than expected on lower costsNovember 14, 2024 | reuters.comMerck KGaA Expects Sales at Lower End of Outlook Range After Third-Quarter MissNovember 14, 2024 | wsj.comMerck KGaA's Cell-Tumor Drug Gets Positive Results in Late-Stage TrialNovember 12, 2024 | morningstar.comMerck & Co., Inc. (MRK) Makes It On UBS’ List Of Stocks For The AI, Growth & Low Rates EraNovember 8, 2024 | msn.comMerck price target lowered to $140 from $145 at Deutsche BankNovember 6, 2024 | markets.businessinsider.comMerck KGaA: A Continued Long-Term Upside Despite Some LagNovember 5, 2024 | seekingalpha.comMerck & Co. Stock: Is Wall Street Bullish or Bearish?November 4, 2024 | msn.comMerck price target lowered to $120 from $140 at BofANovember 1, 2024 | markets.businessinsider.comMerck Reports Steady Q3 2024 Growth Amid ChallengesNovember 1, 2024 | markets.businessinsider.comMerck reports Q3 adjusted EPS $1.57, consensus $1.50October 31, 2024 | markets.businessinsider.comMerck (MRK) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | msn.comMerck & Co Inc. Q3 Profit FallsOctober 31, 2024 | markets.businessinsider.comMerck earnings top estimates amid solid demand for Keytruda cancer drugOctober 31, 2024 | msn.comMerck Cuts FY24 Earnings View, Narrows Sales Forecast After Weak Q3 Earnings - UpdateOctober 31, 2024 | markets.businessinsider.comMerck’s Q3 earnings beat estimates, but company lowers guidanceOctober 31, 2024 | marketwatch.comMerck Q3 Earnings Preview: Focus on Winrevair and KeytrudaOctober 30, 2024 | msn.comA Look Into Merck & Co Inc's Price Over EarningsOctober 29, 2024 | benzinga.comMerck, Moderna launch Phase 3 trial evaluating adjuvant V940, Keytruda comboOctober 28, 2024 | markets.businessinsider.comBank of America Securities Sticks to Their Buy Rating for Merck & Company (MRK)October 25, 2024 | markets.businessinsider.comBarclays Sticks to Its Buy Rating for Merck & Company (MRK)October 24, 2024 | markets.businessinsider.comMerck & Company (MRK) Receives a Buy from JefferiesOctober 23, 2024 | markets.businessinsider.comIs Merck & Co., Inc. (NYSE:MRK) the Most Undervalued Value Stock to Buy According to Analysts?October 23, 2024 | msn.comMerck acquires Modifi Biosciences for $30M upfrontOctober 23, 2024 | markets.businessinsider.comGilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV TreatmentOctober 20, 2024 | markets.businessinsider.comBernstein Initiates Coverage of Merck (MRK) with Market Perform RecommendationOctober 19, 2024 | msn.comMerck RSV therapy cuts respiratory infections by 60% in infantsOctober 19, 2024 | msn.comMerck's Clesrovimab Lowers RSV Disease And Hospitalization In Preterm And Full-term InfantsOctober 17, 2024 | markets.businessinsider.comMerck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...October 17, 2024 | businesswire.comMaintaining Hold on Merck Amid Modest Commercial Prospects for ClesrovimabOctober 11, 2024 | markets.businessinsider.comShould You Invest in Merck & Co. (MRK)?October 11, 2024 | msn.comNew Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and PortfolioOctober 9, 2024 | uk.finance.yahoo.comMerck posts late-stage trial win for Keytruda in head and neck cancerOctober 8, 2024 | msn.comMerck & Co Inc. (MRK): Analysts Are Bullish On This Quality Stock Right NowOctober 6, 2024 | msn.comMerck (MRK) Dips More Than Broader Market: What You Should KnowOctober 3, 2024 | msn.comMerck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon BiopharmaceuticalOctober 1, 2024 | stockhouse.comMerck & Co. Inc. (MRK): A Strong Investment as KEYTRUDA Sales Drive Revenue GrowthSeptember 30, 2024 | msn.comMerck snaps six straight sessions of lossesSeptember 27, 2024 | msn.comEvaxion Biotech Partners With Merck To Expand Vaccine DevelopmentSeptember 26, 2024 | msn.comIs Merck & Co., Inc. (MRK) the Best Cheap Beginner Stock to Invest In?September 26, 2024 | msn.comBarclays Reaffirms Their Buy Rating on Merck & Company (MRK)September 26, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (MRK) and Omnicell (OMCL)September 26, 2024 | markets.businessinsider.comMerck & Co. Inc. (MRK): A Good Undervalued Blue Chip Stock to Buy According to AnalystsSeptember 26, 2024 | msn.comBristol, Merck checkpoint inhibitors focus of FDA advisory committee meetingSeptember 24, 2024 | seekingalpha.comSummit Therapeutics Bests Merck's Top Selling Drug In Phase III TrialSeptember 19, 2024 | seekingalpha.comMerck & Company Buy Rating Justified by Keytruda’s Performance and Gardasil’s Market PotentialSeptember 19, 2024 | markets.businessinsider.com Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter. Email Address 2024 Election Year Stocks: Uncover Hidden Gems! (Ad)In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss. Secure your copy now by clicking this link. MRK Media Mentions By Week MRK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRK News Sentiment▼0.120.47▲Average Medical News Sentiment MRK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRK Articles This Week▼53▲MRK Articles Average Week Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MorphoSys News Today ad pepper media International News Today Genfit News Today Evotec News Today Siemens Healthineers News Today Bayer Aktiengesellschaft News Today Fresenius Medical Care News Today Carl Zeiss Meditec News Today Gerresheimer News Today CompuGroup Medical SE & Co. KGaA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ETR:MRK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
